63.65 USD
↗ 1.62 (2.61%)AT CLOSE (11:59 AM EDT)
Nektar Therapeutics
NKTRNASDAQ • USD
63.62
↘ 0.04 (0.06%)
POST MARKET (AS OF 06:11 PM EDT)
Post Market
AS OF 06:11 PM EDT
63.62
↘ 0.04 (0.06%)
Market: CLOSED
NKTR is currently priced at $63.65. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jun 26, 2026.
Open?$61.52
High?$64.34
Low?$61.29
Prev. Close?$62.03
Volume?6.2M
Avg. Volume?1.1M
VWAP?$62.71
Rel. Volume?5.48x
Bid / Ask
Bid?$51.89 × 100
Ask?$76.08 × 100
Spread?$24.19
Midpoint?$63.99
Valuation & Ratios
Market Cap?2.2B
Shares Out?33.8M
Float?28.9M
Float %?97.4%
P/E Ratio?N/A
P/B Ratio?3.73
EPS?-$4.68
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Themes
Address
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, CA 94158
Phone: (415) 482-5300
SAN FRANCISCO, CA 94158
Phone: (415) 482-5300
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?4
Momentum?97
Short Sent.?26
Piotroski F-Score?2/9Weak
Altman Z-Score?0.24Distress
Confidence?55%Low
Short InterestHigh
Short % of Float?17.11%High
Short Interest?4.9M
Days to Cover?4.9
Free Float28.9M
Avg Daily Volume1.0M
Settlement Date2026-06-15
Financial Health
Current Ratio?10.21Strong
Quick Ratio?10.21Strong
Cash Ratio?2.59Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.73FAIR▾
Peers100
S&P47
P/S?38.65HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-16.2CHEAP▾
S&P97
EV/Sales?35.97HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-27.4%WEAK▾
S&P6
ROA?-20.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-203943000
Enterprise Value?$2.0B
Fundamentals ratios updated end of day